Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Accenture
Fuji
Citi
AstraZeneca
Moodys
Boehringer Ingelheim
Merck
Covington

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,412,992

« Back to Dashboard

Summary for Patent: 4,412,992
Title: 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
Abstract:The present invention provides a pharmaceutical composition for treating ulcerative colitis containing at least one compound of the general formula: ##STR1## wherein X is an --SO.sub.2 -- or --CO-- group and R is either an unsubstituted or substituted non-heterocyclic aromatic ring system or is a radical of the general formula --(CH.sub.2).sub.n --Y, in which Y is a hydroxyl group, an unsubstituted or substituted amino group or a carboxylic or sulphonic acid group and n is a whole number of from 1 to 6 and in which one or more hydrogen atoms in the alkylene radical can be replaced by unsubstituted or substituted amino groups or alkyl radicals and in which the --(CH.sub.2).sub.n --Y radical is either attached directly to the nitrogen atom or via a benzene ring; and/or containing at least one ester thereof and/or at least one non-toxic, pharmaceutically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier. Furthermore, the present invention provides a process for preparing the compounds of the above-given general formulae and also provides a method of treating ulcerative colitis.
Inventor(s): Chan; Rosalind P. K. (London, GB2)
Assignee: Biorex Laboratories Limited (GB2)
Application Number:06/281,504
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Delivery;

Drugs Protected by US Patent 4,412,992

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,412,992

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8023826Jul 21, 1980

International Family Members for US Patent 4,412,992

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 3128819 ➤ Try a Free Trial
France 2493312 ➤ Try a Free Trial
United Kingdom 2080796 ➤ Try a Free Trial
Hong Kong 31885 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Fuji
Merck
Johnson and Johnson
Fish and Richardson
Mallinckrodt
McKinsey
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.